We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We believe our study results support a single LDL-C target, much lower than currently recommended in our guidelines, for all high-risk individuals living with diabetes, whether they have known evidence of hardening of atherosclerosis or not.”
“If you really want to minimize cardiovascular risk in these patients, we really have to add intensive LDL lowering to the mix.”
“I think this study changes the paradigm. In current practice, PCSK9 inhibitors are largely reserved for patients who have had a prior heart attack or stroke, but here we see a benefit of using evolocumab not only to treat patients without a history of heart attack or stroke, but without known significant atherosclerosis. It's a message to physicians and patients that we don't have to wait until someone has atherosclerosis to treat them intensively. We can—and should—be much more proactive.”
No takes yet. Share an insight, caveat, or question.
Good et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: